Investment Thesis
NEXGEL faces a severe liquidity crisis with only $317K cash against negative $1.4M annual free cash flow, providing less than 3 months of operational runway. The company is unprofitable with stagnant revenue growth, persistent operating losses of $3.4M on $11.4M revenue, and negative operating cash flow, indicating fundamental business challenges in the medical device market with no clear path to profitability.
Strengths
- Acceptable gross margin of 39.5% demonstrates product profitability at gross level
- Moderate debt burden with debt-to-equity ratio of 0.13x provides some balance sheet flexibility
- EPS improvement of 24% year-over-year shows marginal operational progress despite losses
Risks
- Critical cash position of $317K with negative $1.4M FCF creates imminent solvency risk with less than 3 months runway
- Quick ratio of 0.75x and negative operating cash flow indicate severe liquidity stress and inability to meet short-term obligations
- Zero revenue growth combined with persistent $3.4M operating losses suggests fundamental market rejection or operational dysfunction
- Negative ROE of -67.3% and ROA of -28.7% indicate severe value destruction for shareholders and inefficient asset utilization
- No insider activity in past 90 days demonstrates complete lack of management conviction in the turnaround
Key Metrics to Watch
- Cash balance and burn rate - potential bankruptcy trigger if cash falls below $100K
- Operating cash flow return to positive - critical inflection point for viability
- Revenue growth acceleration - current 0% growth unsustainable for surgical device company
Financial Metrics
Revenue
11.4M
Net Income
-3.0M
EPS (Diluted)
$-0.38
Free Cash Flow
-1.4M
Total Assets
10.5M
Cash
317.0K
Profitability Ratios
Gross Margin
39.5%
Operating Margin
-29.3%
Net Margin
-26.3%
ROE
-67.3%
ROA
-28.7%
FCF Margin
-12.1%
Balance Sheet & Liquidity
Current Ratio
1.47x
Quick Ratio
0.75x
Debt/Equity
0.13x
Debt/Assets
53.2%
Interest Coverage
-223.47x
Long-term Debt
588.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-13T10:09:19.838841 |
Data as of: 2025-12-31 |
Powered by Claude AI